Recent Updates
Recently added Catalysts
NTHI Positive Sentiment

NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors

Wednesday, September 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: NeOnc Technologies Holdings, Inc. has announced the pricing of a $15 million registered direct offering under Nasdaq rules. The offering is targeted at both new and existing institutional investors. This funding is expected to bolster the company's efforts in developing therapies for central nervous system cancers.

Market Sentiment Analysis

POSITIVE FACTORS

  • NeOnc Technologies has successfully priced a $15 million offering.
  • The offering is aimed at both new and existing institutional investors.
  • This funding could support the development of novel CNS cancer therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Perillyl alcohol
Phase 1 · Glioblastoma Multiforme

Full Press Release Details

CALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into

Frequently Asked Questions

What is the amount of NeOnc's recent offering?

NeOnc Technologies announced a $15 million registered direct offering.

Who are the investors in NeOnc's offering?

The offering is aimed at both new and existing institutional investors.

What is the purpose of the funding for NeOnc?

The funding will support the development of therapies for CNS cancers.

ShareAdd on Google
Tags: NTHI Viatris Investor Conferences Healthcare NeOnc Technologies CNS cancers biopharmaceutical direct offering
Last updated: Sep 9, 2026

Biotech snapshot

Cash runway
$2M liquidity · $2M/mo burn
~1 mo
High dilution risk
Lead asset
Perillyl alcoholPhase 1
Glioblastoma Multiforme →